

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: De Haen et al.

Examiner: Brandon J. FETTEROLF

Serial No.: 10/532,446

Art Unit: 1626

Filing Date: April 22, 2005

For: METHOD FOR THE SELECTIVE AND QUANTITATIVE FUNCTIONALIZATION OF IMMUNOGLOBULIN FAB FRAGMENTS, CONJUGATE COMPOUNDS OBTAINED WITH THE SAME AND COMPOSITIONS THEREOF

**Certificate of Mailing and/or Transmission Under 37 C.F.R. § 1.8(a)(1)(i)(A)(ii)**

I hereby certify that the following correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or being facsimile transmitted to the USPTO (571) \_\_\_\_\_, on the date indicated below:

1. Information Disclosure Transmittal: 2pp;
2. Forms PTO/SB/08B: 1pg; and
3. Copy of the 2 cited articles: 16 pp total

Date: October 12, 2007

Signature: \_\_\_\_\_

Pamela J. Gewirtz

Mail Stop Amendments  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §§§ 1.56, 1.97 AND 1.98**

Dear Sir:

Supplemental to the Information Disclosure Statement filed January 11, 2007, applicants respectfully submit this Information Disclosure Statement listing additional art cited in the related Chinese application no. 200380103208.6, whose national phase entry date is May 13, 2005.

It is respectfully requested that this Information Disclosure Statement and the references identified on the enclosed Forms PTO/SB/08B, a copy of which is attached be considered during the pendency of the prosecution of the immediate application pursuant to §§§ 1.56, 1.98 and 1.97:

- (b) An information disclosure statement shall be considered by the Office if filed by the applicant within any one of the following time periods:

☐

- (1) within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d)

☐

- (2) within three months of the date of entry of the national stage as set forth in § 1.491 in an international application

- ☒ (b) (3) before the mailing of a first Office action on the merits; or
- ☐ (b) (4) before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- ☒ (g) An information disclosure statement filed in accordance with section shall not be construed as a representation that a search has been made
- ☒ (h) The filing of an information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b).

Applicants further request that:


1. The references identified on the enclosed Form PTO/SB/08B be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The enclosed Form PTO/SB/08B be appropriately initialed by the Examiner, and a copy of same be returned to Applicants' attorney.

Under 37 CFR § 1.17(p), the fee of \$180.00 is not believed to be due with the filing of this Information Disclosure Statement as it is not being filed under 37 C.F.R. § 1.97(c) or (d). However, the Director is hereby authorized to charge any fees due, or credit any overpayments to Deposit Account No. 50-2168.

Early and favorable action is hereby requested.

October 12, 2007  
Date

Respectfully submitted,



M. Caragh Noone  
Attorney for Applicant  
Reg. No.: 37,197  
Bracco Research USA Inc.  
305 College Road East  
Princeton, NJ 08540  
(609) 514-2454  
(609) 514-2446